Evotec stock: At 61.23 percent below its 52-week high, Evotec stock trades at EUR 2.83

Published on 10/23/2026 at 16:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Eight analysts set a EUR 4.44 average target in October. Evotec stock costs EUR 2.83 on October 23, 2026, minus 0.35 percent versus the Xetra close.

Price position and valuation

Evotec stock trades 61.23 percent below its 52-week high.
Eight analysts give Evotec an average target of EUR 4.44.
Evotec stock costs EUR 2.83 at Lang & Schwarz, minus 0.35 percent versus the Xetra close.
Full third-quarter and nine-month results are scheduled for November 5, 2026.

Isometrische 3D-Illustration einer Wirkstoffforschungs-Wertschöpfungskette mit Molekülen und Laborrobotern — Isometrische 3D-Grafik zeigt den Wirkstoffscreening-Prozess der Biotech-Branche von Evotec SE, ISIN DE0005664809, als Wertschöpfungskette, Illustration mit AI erstellt.

Evotec SE stock (ISIN DE0005664809) trades 61.23 percent below its 52-week high of EUR 7.30, putting the biotech company's price position ahead of its next financial checkpoint. The stock was trading at EUR 2.83 at Lang & Schwarz on October 23, 2026 at 4:04 p.m. CEST, minus 0.35 percent versus the Xetra close of October 22, 2026 at EUR 2.84.

Analyst target remains above price

MarketScreener lists an average target of EUR 4.443 from eight analysts, giving the consensus a rounded value of EUR 4.44. The average target is materially above the Lang & Schwarz price, while the consensus rating is Hold, according to MarketScreener.

Stock stays near its yearly low

Evotec's 52-week range is EUR 2.41 to EUR 7.30 as of October 23, 2026. The current euro price is EUR 0.42 above the low and EUR 4.47 below the high. Trading volume stood at 387,290 shares, compared with an average volume of 979,535 shares.

Loss outlook shapes valuation

Evotec reported preliminary revenue of EUR 465.0 million for the first nine months of 2026 and adjusted EBITDA of minus EUR 42.8 million. The company confirmed full-year 2026 revenue guidance of EUR 570.0 million to EUR 610.0 million and adjusted EBITDA guidance of minus EUR 70.0 million to minus EUR 105.0 million in the release carried by finanzen.net on October 13, 2026. The same release said the preliminary figures exceeded market expectations, but the company left its annual outlook unchanged.

The next scheduled date is November 5, 2026, when Evotec plans to publish full third-quarter and nine-month results, according to finanzen.net. Evotec's investor-relations page describes a drug-discovery and development business built around pharmaceutical partnerships, data-driven research and Just - Evotec Biologics.

Comparison with peers

Evotec: minus 0.35 percent, P/E minus 2.50, market capitalization EUR 501.2 million.

Bayer (Xetra, EUR): minus 1.38 percent, P/E minus 24.80, market capitalization EUR 42.8 billion.

Sartorius (Xetra, EUR): plus 1.72 percent, P/E 97.70, market capitalization EUR 17.0 billion.

Price remains below the high

The 61.23 percent gap to the yearly high keeps the chart position central, while the negative adjusted EBITDA guidance sets a fundamental counterweight to the EUR 4.44 average analyst target.

Evotec was trading at EUR 2.83 at Lang & Schwarz on October 23, 2026 at 4:04 p.m. CEST, minus 0.35 percent versus the Xetra close of October 22, 2026 at EUR 2.84. The further course of trading is shown by the continuously updated real-time quote of Evotec stock.